NKARTA has become an intriguing speculative investment for me because the company is developing natural killer (NK) cell therapies that could offer advantages over traditional cell therapies in terms of safety, scalability, and accessibility.
While many biotechnology companies remain focused on crowded areas of oncology, NKARTA is pursuing a differentiated platform with the potential to address multiple blood cancers and autoimmune diseases.
The company's technology is designed to create off-the-shelf treatments that could be manufactured more efficiently than personalized therapies, which may provide a significant commercial advantage if clinical data continues to improve.
Trading based on absolutely no 'clinical trial' success - and well below it's current cash-value, any news at all of positive read-outs will send this stock higher like my previous call on $CAPR Capricor.
Like all past posts, they got lots of doubt, hate, and accusations of failure; however, like all-biotech bets, NKARTA is a unique one, and I have purchased 350,000 shares at average cost of $2.55.
If the initial topline results are positive, I'd expect $8-10/market capitalization share price on this play inclusive of cash value and zero debt.
$NKTX - PT: $8-10/share